ATF2 and cardiomyopathy: Our findings highlight a critical mechanism underlying the pathogenesis of DCM and suggest that targeting CHOP or perhaps ATF2 should be considered as an approach for the treatment of DCM and in particular the cardiomyopathy due to the FBXO32 mutation (Fig. 7).